An update on the management of hepatitis C virus and human immunodeficiency virus co-infection-Reference-Cited by-同舟云学术

An update on the management of hepatitis C virus and human immunodeficiency virus co-infection

Published:2019-03 Issue:3 Volume:14 Page:185-195
ISSN:1746-0794
Container-title:Future Virology
language:en
Short-container-title:Future Virology

Author:

Tolentino Bryan¹,Singh Ritu R²,Misra Suresh²,Dieterich Douglas T³,Sarpel Dost¹

Affiliation:

1. Department of Medicine, Division of Infectious Disease, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

2. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

3. Department of Medicine, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Abstract

An estimated 2.3 million people globally are co-infected with HIV and HCV. Liver disease is now a leading cause of non-AIDS-related mortality among HIV-infected patients. The development of direct-acting antiviral agents has revolutionized the treatment of HIV/HCV co-infection with sustained virologic response response rates above 95% in most patient populations. This article provides an update on the management of acute and chronic HCV in patients co-infected with HIV including a section on drug–drug interactions.

Publisher

Future Medicine Ltd

Subject

Virology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fvl-2018-0116

Reference99 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

2. Global epidemiology and genotype distribution of the hepatitis C virus infection

3. Centers for Disease Control and Prevention (CDC), NCHHSTPD. Viral hepatitis surveillance United States, 2015 Surveillance for Viral Hepatitis – United States. 73 (2015). www.cdc.gov/hepatitis/statistics/2015surveillance/index.htm.